New Challenges for Natural and Vaccine-Induced Immunity against HBV Infection: Second Edition

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue on “New Challenges for Natural and Vaccine-Induced Immunity against HBV Infection” (https://www.mdpi.com/journal/vaccines/special_issues/HBV_vaccine).

The availability of an effective vaccine against hepatitis B infection has produced a strong decline in the number of new cases of HBV-related hepatitis worldwide. However, the coverage of anti-HBV vaccination remains suboptimal in many geographical areas, with the most relevant drop occurring in low-income countries. Accordingly, HBV infection remains an important public health problem, with over 250 million chronically infected patients worldwide.

It is worth noting that, despite the overall high efficacy of anti-HBV vaccination, a non-negligible (but not well-defined) ratio of persons are “non-responders” to the vaccine, failing to achieve a protective concentration of antibodies able to prevent HBV infection. This aspect could be particularly critical in special populations with impaired immune responses, such as patients with hematological malignancies or HIV infection. Overall, the rate of non-responders, the host factors predisposing to a reduced or lack of response to anti-HBV vaccination, and the long-term kinetics of anti-HB antibodies remain poorly investigated.

Another potential pitfall of HBV vaccination, and more generally of immune control of HBV, is related to the circulation of viral strains, carrying mutations in the surface antigen (HBsAg), which have been demonstrated to alter the affinity of antibodies, both naturally produced by the immune system and induced by vaccination. The circulation of these variants deserves careful monitoring since they can be transmitted to vaccinated people or favor HBV reactivation events.

For this Special Issue, we welcome all original research papers, reviews, clinical cases, and methodological novelties able to shed new light on the immune response to HBV infection, including that induced by anti-HBV vaccination, and on the role of HBV genetic variability in modifying the ability of the immune system and vaccination to prevent/control HBV infection.

Dr. Romina Salpini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• anti-HBV vaccine
• HBV variability
• vaccine escape
• anti-HBV immune response
• immune-suppression-driven HBV reactivation
• anti-HBs titer
• nti-HBc titer
• HBsAg antigenicity
• anti-HBV immunomodulators
• non-responders